Pancreatic Cancer Research

ResearcherSt. Jude Children's Research HospitalActive in the last 2 years

Christopher R. Vakoc

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-1158-7180; OpenAlex author ID A5015010943; NIH RePORTER profile ID 10647942. Sources: funder_awards.

Their work

Papers
16 (first author 1, last author 7)
Trials
0
Grants
3
Labs led
2
Collaborators
44
Papers, trials and grants by year

2016: 1 grant · 2017: 3 papers · 2018: 2 papers · 2019: none · 2020: 4 papers · 2021: none · 2022: 1 paper · 2023: 1 paper · 2024: 4 papers · 2025: 1 paper · 2026: 2 grants

Papers 16

  1. KLF5 enables dichotomous lineage programs in pancreatic cancer via the AAA+ ATPase coactivators RUVBL1 and RUVBL2. Last author DOI 10.1038/s41467-025-66007-0↗
  2. Engrailed-1 Promotes Pancreatic Cancer Metastasis. Co-author DOI 10.1002/advs.202308537↗
  3. Interaction between MED12 and ΔNp63 activates basal identity in pancreatic ductal adenocarcinoma. Last author DOI 10.1038/s41588-024-01790-y↗
  4. A ΔNp63-MED12 axis drives basal-like identity in pancreatic cancer. First author DOI 10.1038/s41588-024-01797-5↗
  5. A mucus production programme promotes classical pancreatic ductal adenocarcinoma. Co-author DOI 10.1136/gutjnl-2023-329839↗
  6. p73 activates transcriptional signatures of basal lineage identity and ciliogenesis in pancreatic ductal adenocarcinoma Last author DOI 10.1101/2023.04.20.537667↗
  7. SPDEF promotes the classical subtype of pancreatic ductal adenocarcinoma Co-author DOI 10.1101/2022.03.18.484951↗
  8. ZBED2 is an antagonist of interferon regulatory factor 1 and modifies cell identity in pancreatic cancer. Last author DOI 10.1073/pnas.1921484117↗
  9. SOAT1 promotes mevalonate pathway dependency in pancreatic cancer. Co-author DOI 10.1084/jem.20192389↗
  10. Intraductal Transplantation Models of Human Pancreatic Ductal Adenocarcinoma Reveal Progressive Transition of Molecular Subtypes. Co-author DOI 10.1158/2159-8290.cd-20-0133↗
  11. Squamous trans-differentiation of pancreatic cancer cells promotes stromal inflammation. Last author DOI 10.7554/elife.53381↗
  12. TP63-Mediated Enhancer Reprogramming Drives the Squamous Subtype of Pancreatic Ductal Adenocarcinoma. Last author DOI 10.1016/j.celrep.2018.10.051↗
  13. Organoid Profiling Identifies Common Responders to Chemotherapy in Pancreatic Cancer. Co-author DOI 10.1158/2159-8290.cd-18-0349↗
  14. Enhancer Reprogramming Promotes Pancreatic Cancer Metastasis. Last author DOI 10.1016/j.cell.2017.07.007↗
  15. Untangling the genetics from the epigenetics in pancreatic cancer metastasis. Co-author DOI 10.1038/ng.3798↗
  16. Soils and Seeds That Initiate Pancreatic Cancer Metastasis. Co-author DOI 10.1158/2159-8290.cd-17-0887↗

Grants 3

  1. Project 2: Splicing Dysregulation in Cancer P01CA013106↗
  2. Targeting aberrant enhancer landscapes in pancreatic cancer R01CA229699↗
  3. Enhancer Reprogramming as a Driver of Pancreatic Cancer Progression AWARD pancan:2016-christopher-vakoc-md-phd-enhancer-reprogramming-as-a-driver-of-pa

Closest collaborators

The 25 strongest of 44 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. David Arthur Tuveson · 11 shared papers, 2017–2024 · strength 1.35
  2. Camila dos Santos · 1 shared paper, 1 shared grant, 2024–2026 · strength 1.03
  3. David L Spector · 1 shared paper, 1 shared grant, 2024–2026 · strength 1.03
  4. Adrian R. Krainer · 1 shared paper, 1 shared grant, 2024–2026 · strength 1.03
  5. Diogo Maia-Silva · 6 shared papers, 2018–2025 · strength 0.91
  6. Tim D.D. Somerville · 7 shared papers, 2017–2023 · strength 0.69
  7. Youngkyu Park · 6 shared papers, 2017–2024 · strength 0.69
  8. Mikala Egeblad · 4 shared papers, 2017–2025 · strength 0.57
  9. Claudia Tonelli · 4 shared papers, 2020–2024 · strength 0.57
  10. Diogo Maia-Silva · 1 shared paper, 2024 · strength 0.46
  11. Damianos S. Skopelitis · 2 shared papers, 2024–2025 · strength 0.43
  12. Patrick Cunniff · 2 shared papers, 2024–2025 · strength 0.43
  13. Stella K. Hur · 3 shared papers, 2020–2023 · strength 0.40
  14. Chang‐Il Hwang · 4 shared papers, 2017–2024 · strength 0.37
  15. Hervé Tiriac · 4 shared papers, 2017–2024 · strength 0.37
  16. Koji Miyabayashi · 4 shared papers, 2017–2020 · strength 0.30
  17. Michael Anthony Hollingsworth · 3 shared papers, 2017–2024 · strength 0.30
  18. Faiyaz Notta · 2 shared papers, 2020–2023 · strength 0.27
  19. Nicole Sivetz · 1 shared paper, 2025 · strength 0.27
  20. Ralph H. Hruban · 2 shared papers, 2020–2024 · strength 0.26
  21. Hao Yuan · 2 shared papers, 2020–2022 · strength 0.23
  22. Jean L. Grem · 2 shared papers, 2017–2024 · strength 0.21
  23. Jae‐Seok Roe · 2 shared papers, 2017–2024 · strength 0.21
  24. Paul M. Grandgenett · 2 shared papers, 2017–2024 · strength 0.21
  25. Giulia Biffi · 2 shared papers, 2020 · strength 0.18

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.